

PETAR MAMULA  
JONATHAN E. MARKOWITZ  
ROBERT N. BALDASSANO  
*EDITORS*

# Pediatric Inflammatory Bowel Disease

 Springer

# **Pediatric Inflammatory Bowel Disease**

# Pediatric Inflammatory Bowel Disease

*Edited by*

**Petar Mamula, M.D.**

*Assistant Professor of Pediatrics,  
University of Pennsylvania School of Medicine,  
Attending Physician, Division of GI,  
Hepatology and Nutrition, Director,  
Endoscopy Suite, The Children's Hospital of Philadelphia,  
Philadelphia, Pennsylvania*

**Jonathan E. Markowitz, M.D., M.S.C.E**

*Associate Professor of Clinical Pediatrics,  
University of South Carolina School of Medicine,  
Attending Physician, Children's Center for Digestive Health,  
Greenville Hospital System University Medical Center,  
Greenville, South Carolina*

**Robert N. Baldassano, M.D.**

*Professor, University of Pennsylvania School of Medicine,  
Attending Physician and Director, Inflammatory Bowel  
Disease Center, Division of GI, Hepatology and Nutrition,  
The Children's Hospital of Philadelphia,  
Philadelphia, Pennsylvania*

Petar Mamula, M.D.  
Assistant Professor of Pediatrics  
University of Pennsylvania School of Medicine  
Attending Physician, Division of GI  
Hepatology and Nutrition  
Director, Endoscopy Suite  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

Jonathan E. Markowitz, M.D., M.S.C.E.  
Associate Professor of Clinical Pediatrics  
University of South Carolina School of Medicine  
Attending Physician, Children's Center for  
Digestive Health  
Greenville Hospital System University  
Medical Center  
Greenville, South Carolina

Robert N. Baldassano, M.D.  
Professor  
University of Pennsylvania School of Medicine  
Attending Physician and Director  
Inflammatory Bowel Disease Center  
Division of GI, Hepatology and Nutrition  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

Library of Congress Control Number: 2007929784

ISBN-13: 978-0-387-73480-4

e-ISBN-13: 978-0-387-73481-1

Printed on acid-free paper.

© 2008 Springer Science+Business Media, LLC

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

9 8 7 6 5 4 3 2 1

springer.com

*We dedicate this book...  
To our families.*

*To Gordana-Dana, to Kay, and to Joanne. For their love, understanding and  
encouragement.*

*To Niko, to Jack, Leo, and Benjamin, and to Chris, Steven, and Julie.  
For making us believe that the best is yet to come.*

*To our colleagues everywhere, past and present. For working hard each day to  
make a difference.*

*To our patients. For inspiring us.  
Petar, Jon, Robert*

# Foreword

Pediatric Inflammatory Bowel Diseases (IBD) are the most common and most significant chronic disorders in Pediatric Gastroenterology. The onset of Crohn disease and ulcerative colitis in the first two decades of life presents a number of diagnostic and therapeutic challenges that are unique to pediatric patients. Although the studies available for pediatric diagnosis have improved dramatically in the past three decades, the improvement in technology alone cannot account for the increased frequency of IBD recognized in early childhood. While therapy for older patients has improved dramatically with the use of immunomodulators and the development of exciting biologic strategies, rarely if ever have comprehensive studies of the pharmacokinetics, safety and efficacy of any of the IBD medications been performed in pediatric patients. A number of excellent medications are not available in liquid preparations that can be swallowed by children, and others, such as timed-release formulations, are developed for delivery to an adult gastrointestinal tract. It is unfortunate that the care we provide to children is often an extrapolation of what is known about and available for adults with IBD.

Pediatric patients with IBD face a number of unique challenges. The onset of disease before puberty can be devastating. Growth failure is a particularly difficult problem with potentially permanent consequences. Much of the pediatric specific research has focused on the role of nutritional therapy to treat growth failure and induce remission. Strategies such as nocturnal nasogastric administration of supplements are widespread in most pediatric centers, and are surprisingly well-tolerated even by the youngest patients, particularly when the value of nutritional therapy is presented in advance to both the family and the child. Nutrition must be strongly advocated for pediatric patients, as it has great therapeutic value, and it is the only therapy for which there are no serious potential complications.

The long-term consequences of medical and surgical therapy are particularly troubling for pediatric patients. The complications of corticosteroids in childhood and adolescence can seem worse than the disease itself. While most of the cosmetic side effects are reversible, the psychological trauma to an adolescent can be overwhelming. We are only beginning to understand and address the long term consequences of therapy given at an early age. Bone mass accumulation and linear growth are critical processes that are age dependent, with peaks in early adolescence. Failure of therapy at this stage will have permanent, and possibly debilitating consequences. In order to spare cumulative steroid exposure there has been a marked shift in the last two decades to immunodulator therapies, often initiated in the first decade of life. More recently, biologic therapy has resulted in a dramatic shift in therapeutic armamentarium and the style of its administration. In adults, the “therapeutic pyramid” has been turned on all of its sides, with a resulting dramatic improvement in quality of life and a decrease in overall corticosteroid exposure, but with a new set of adverse events from therapy. While pediatric patients undoubtedly benefit from the adult data supporting these “bottom up” and “top down” strategies, the data in adults does not necessarily predict the optimal strategies for children. The effects of more “aggressive” therapy are being recognized for their positives and negatives, and the risks and benefits in pediatrics are undoubtedly different in children and adolescents. Whether it is the state of the immature immune

system, the effect of rapid growth, or the background susceptibility to different malignancies at different ages, the incidence of profound problems such as hepatosplenic T cell lymphomas reminds all practitioners that we do not understand the unique aspects of the younger patient that confer such increased susceptibility.

There is no better care than that given by a well educated and experienced practitioner who considers all aspects of a patient's problems. This book is designed for those practitioners who care for children. IBD therapy must be customized for each individual patient. There is no more ultimate "individual" patient than a child or adolescent with IBD. The many challenges of growth, nutrition, psychology and adaptation weigh heavily upon the profound challenges of pediatric Crohn disease and ulcerative colitis. In addition to the need for induction and maintenance of remission, the pediatric gastroenterologist must be obsessed with the long term consequences of therapy, not just a decade away, but hopefully a half century or more hence. Although these patients will move on to adult gastroenterologists, the problems will only accumulate and multiply. "Above all else, do no harm" is a wise admonition for pediatric IBD, where therapies are rapidly improving and there is a great potential for a cure of these devastating illnesses. These therapies and ultimate cures for Crohn disease and ulcerative colitis will come from the extraordinary advances in immunology and immunogenetics that are well detailed in this book. Until that time, we must rely on the conventional approaches developed in adults, but with the conviction to verify their efficacy for children with IBD.

This book is a landmark step toward better understanding of pediatric IBD and the challenges of IBD therapy in children. The editors are highly respected clinical scientists who have each contributed substantially to the knowledge about pediatric IBD. In addition, their knowledge gained from their extensive clinical experience is reflected in this book. They have assembled a truly extraordinary group of authoritative leaders whose contributions to this volume will guarantee that this will be a reference for all who care for pediatric IBD. The book is a tribute to those authors, but is dedicated to the children and adolescents with Crohn disease and ulcerative colitis. It is a sign of the times that increased focus at every level is directed toward these children, and this book is one significant step along the road toward improving care for the hundreds of thousands of children with inflammatory bowel diseases. It should be required reading for all those who care for these children.

# Preface

As this first edition of Pediatric Inflammatory Bowel Disease goes to press, we find ourselves reflecting not only upon our hopes and expectations for the textbook, but also upon the discipline of caring for children with inflammatory bowel disease (IBD). We have been saying amongst ourselves for several years that the time has come for a textbook dedicated to the unique aspects of pediatric IBD. This does not imply that the existing textbooks on IBD and pediatric gastroenterology are not useful. Rather, it is a testament that the collective knowledge about children and adolescents with IBD has grown, and continues to grow, to a point that warrants its own volume.

Despite its growth, the community of pediatric gastroenterologists remains a fairly intimate one. We were fortunate to have a highly talented and internationally renowned group of physician-scientists who shared our vision for this project and willingly contributed their time and effort to provide the chapters for the book. However, we also recognize that there remain many geographic regions where access to specialists trained to care for children with IBD is limited. To this end, we have tried to design this book as a resource for not just pediatric gastroenterologists, but also for general pediatricians, internists, family practitioners, and internist-gastroenterologists who will likely care for children or adolescents with IBD at some point in their practice. We also aimed to maintain the focus of this book on the pediatric aspects of IBD, rather than simply recapitulating the excellent general IBD textbooks already available. This was easier in some chapters than others, highlighting both the progress that has been made in studying IBD in children and also the need for further pediatric based studies. Also included is a unique section highlighting some topics such as advocacy, and transition of care from pediatric- to internist-gastroenterologists—areas where even experienced physicians may need guiding resources.

Pediatric IBD continues to grow as a discipline, and certainly many changes have occurred over the past few years. Our understanding of the immune system and its interplay with the environment and genetic susceptibilities has vastly improved providing us with further insight into the etiology and pathogenesis of the constellation of disorders that are defined by the term IBD. New approaches to treatment have been discovered, and new drugs developed. This textbook discusses these new approaches to treatment and aims at improving one's knowledge of the pathogenesis, epidemiology, diagnosis, and treatment of Pediatric IBD. We hope that our readers will profit by the collective experience, resulting in improved care for children afflicted by IBD.



# Contents

Foreword.....	vii
Preface.....	ix
Contributors.....	xxiii

## Section 1 Etiology and Pathogenesis

Chapter 1. Genetics of Inflammatory Bowel Diseases.....	3
<i>Nancy McGreal and Judy H. Cho</i>	
Introduction.....	3
Crohn Disease and Ulcerative Colitis: Genetic Epidemiology.....	4
Identifiable Gene Variants in Crohn Disease.....	5
Genome-wide Association Studies in Crohn Disease.....	7
Genetic Studies in Ulcerative Colitis.....	8
Genotype-Phenotype Correlations in Pediatric IBD.....	9
Summary.....	11
Chapter 2. Gut Immunity and Inflammatory Bowel Disease.....	15
<i>William A. Faubion and Claudio Fiocchi</i>	
Introduction.....	15
Innate Intestinal Immunity and IBD.....	16
Development of the Epithelial Barrier and Innate Immune Cells.....	19
Adaptive Intestinal Immunity and IBD.....	19
Putting it all Together: Integrating Gut Microbes, Epithelial Cells, and Lymphocytes in the Pathogenesis of IBD.....	23
Innate and Adaptive Immune Responses Unique to Pediatrics.....	24
Summary.....	25
Chapter 3. Cytokines and Inflammatory Bowel Disease.....	31
<i>Edwin F. de Zoeten and Ivan J. Fuss</i>	
Introduction.....	31
Pro-inflammatory Cytokines.....	32
Anti-inflammatory Cytokines.....	37
Summary.....	39

## Section 2 Epidemiology and Clinical Features

Chapter 4. Epidemiology of Pediatric Inflammatory Bowel Disease.....	45
<i>Shehzad Saeed and Subra Kugathasan</i>	

Introduction.....	45
Descriptive Epidemiology .....	46
Hygiene Hypothesis and Other Epidemiological Observation in IBD .....	49
Environmental Risk Factors .....	51
Appendectomy .....	53
Breast Feeding .....	53
Dietary Factors .....	53
Drugs.....	54
Socio-Economical, Educational and Occupational Status .....	54
Stress .....	55
New Epidemiology .....	55
Genetic Epidemiology & its Impact on the Pathogenesis of IBD .....	55
Challenges in the Way Forward; Genes and Environmental Interactions.....	55
IBD Among New Populations .....	56
New Approaches.....	56
Summary .....	57
 Chapter 5. Early Onset Inflammatory Bowel Disease- Epidemiology and Clinical Features . . . . .	61
<i>Melvin B. Heyman and Neera Gupta</i>	
Introduction.....	61
Epidemiology of Pediatric Inflammatory Bowel Disease .....	61
Clinical Features of Pediatric Inflammatory Bowel Disease .....	63
 Chapter 6. The Natural History of Pediatric Crohn Disease . . . . .	67
<i>James Markowitz</i>	
Introduction.....	67
Disease Activity.....	67
Evolution of Disease Phenotype .....	68
Growth .....	69
Corticosteroid Dependence.....	69
Surgery .....	69
Postoperative Recurrence .....	70
Cancer Risk.....	70
Quality of Life .....	72
 Chapter 7. Natural History of Pediatric Ulcerative Colitis . . . . .	75
<i>Jeffrey S. Hyams</i>	
Introduction.....	75
Historical Perspective – Children.....	75
Historical Perspective – Adults.....	76
Clinical Characteristics Influencing Course.....	77
Drug Modification of Natural History .....	77
Can We Predict the Course of Disease?.....	79
Summary .....	79
 Chapter 8. Natural History of Pediatric Indeterminate Colitis . . . . .	83
<i>Michael D. Kappelman and Richard J. Grand</i>	
Introduction.....	83
Factors Leading to a Diagnosis of Indeterminate Colitis.....	84

Definitions.....	85
Epidemiology.....	85
Natural History.....	86
Recommendations.....	89
Summary.....	89
 Chapter 9. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease . . . .	91
<i>Shervin Rabizadeh and Maria Oliva-Hemker</i>	
Introduction.....	91
Growth Failure.....	92
Joint Manifestations.....	93
Bone Disease.....	93
Oral Lesions.....	94
Skin Lesions.....	94
Eye Lesions.....	96
Liver Disease.....	97
Other Extraintestinal Manifestations.....	98
Summary.....	99
 Chapter 10. Growth Impairment in Pediatric Inflammatory Bowel Disease . . . . .	103
<i>Thomas D. Walters and Anne M. Griffiths</i>	
Introduction.....	103
Normal Growth and Pubertal Development.....	103
Growth in Pediatric IBD.....	104
Pathophysiology of Growth Impairment in IBD.....	107
Facilitation of Normal Growth in IBD.....	110
General Principles of Management.....	110
Summary.....	114
 Chapter 11. Skeletal Health in Pediatric Inflammatory Bowel Disease . . . . .	119
<i>Francisco Sylvester</i>	
Introduction.....	119
Growth, Bone Modeling and Remodeling.....	119
Bone Cells and Inflammation.....	121
Effects of Intestinal Inflammation on Bone.....	123
Conclusions.....	128
 Chapter 12. Puberty and Pediatric-Onset Inflammatory Bowel Disease . . . . .	133
<i>Barbara S. Kirschner and Barry H. Rich</i>	
Introduction.....	133
The Pubertal Process in Healthy Children and Adolescents.....	133
The Influence of Inflammatory Bowel Disease on Puberty.....	135
Pubertal Arrest.....	136
Potential Causes of Pubertal Delay in Patients with IBD.....	136
Psychosocial Issues and Puberty.....	139
Therapeutic Approach to Addressing Pubertal Issues in IBD.....	139
 Chapter 13. Classification of Pediatric Inflammatory Bowel Disease . . . . .	143
<i>Athos Bousvaros</i>	
Introduction.....	143
Diagnostic Evaluation of Inflammatory Bowel Disease.....	143

Distinguishing Acute Self-limited Colitis from Inflammatory Bowel Disease Involving the Colon .....	144
Distinguishing Ulcerative Colitis from Crohn Disease .....	145
“Indeterminate Colitis” or “Colonic IBD Type Unclassified” .....	150
Subclassification of Ulcerative Colitis and Crohn Disease.....	152
Summary .....	153

**Section 3 Diagnosis**

Chapter 14. The History and Physical Exam in Pediatric Inflammatory Bowel Disease .....	159
<i>Cheryl Blank and David J. Keljo</i>	
Introduction.....	159
History.....	159
Physical Exam .....	161
Conclusion .....	162
Chapter 15. Differential Diagnosis of Pediatric Inflammatory Bowel Disease .....	165
<i>Thierry Lamireau</i>	
Introduction.....	165
Acute Onset Diarrhea .....	165
Chronic or Recurrent Intestinal Symptoms.....	167
Abdominal Mass.....	172
Isolated Esophagogastrroduodenal Involvement.....	173
Isolated Perianal Disease.....	173
Chapter 16. Laboratory Evaluation of Pediatric Inflammatory Bowel Disease .....	179
<i>Jennifer Strople and Benjamin D. Gold</i>	
Introduction.....	179
Blood Tests .....	179
Stool Evaluation .....	186
Summary .....	187
Chapter 17. Radiologic Evaluation of Pediatric Inflammatory Bowel Disease .....	193
<i>Benedict C. Nwomeh and Wallace V. Crandall</i>	
Introduction.....	193
Crohn Disease.....	193
Imaging Techniques .....	194
Ulcerative Colitis .....	198
Imaging Techniques .....	198
Indeterminate Colitis .....	200
Other Radiologic Modalities in IBD.....	200
Evaluation of Complications .....	202
Extraintestinal Disease .....	205
Hepatobiliary Disease.....	205
Bone and Joint Disease .....	205
Future Trends.....	206

Chapter 18. Endoscopic Modalities in Pediatric Inflammatory Bowel Disease . . . . .	211
<i>Krishnappa Venkatesh and Mike Thomson</i>	
Introduction.....	211
Endoscopy – Background History .....	211
Patient Preparation.....	212
Bowel Preparation .....	213
Monitoring and Sedation.....	214
Endoscopic Techniques in Inflammatory Bowel Disease .....	215
Ileocolonoscopy .....	217
Ileocolonoscopy Basic Technique.....	218
Complications of Ileocolonoscopy .....	226
Endoscopic Findings in Inflammatory Bowel Disease.....	227
Follow-up and Surveillance Ileocolonoscopy .....	228
Enteroscopy.....	229
Double Balloon Enteroscopy.....	231
Endosonography .....	233
New Endo-diagnostic Methods .....	234
Summary .....	235
Chapter 19. The Pathology of Chronic Inflammatory Bowel Disease . . . . .	241
<i>Pierre Russo</i>	
Introduction.....	241
Major Histologic Features Noted in Mucosal Specimens .....	241
Pathologic Features of Ulcerative Colitis and Crohn Disease .....	243
Ulcerative Colitis.....	245
Crohn Disease.....	248
Backwash Ileitis.....	254
Upper GI Tract Involvement in UC.....	255
Chapter 20. Video Capsule Endoscopy in Pediatric Inflammatory Bowel Disease . . . . .	263
<i>Marc Girardin and Ernest G. Seidman</i>	
Introduction.....	263
Potential Uses of Capsule Endoscopy for Inflammatory Bowel Disease .....	265
Detection of Post-operative Recurrence.....	267
Indeterminate Colitis .....	267
Experience in Pediatric Inflammatory Bowel Disease .....	267
Specificity of Capsule Findings .....	267
Practical Issues in Pediatric Patients.....	268
Conclusions.....	271
Chapter 21. Bone Health Assessment in Pediatric Inflammatory Bowel Disease . . . . .	275
<i>Meena Thayu, Edisio Semeao and Mary B. Leonard</i>	
Introduction.....	275
Skeletal Modeling and Bone Accrual During Childhood.....	276
Changes in Cortical and Trabecular Bone with Growth .....	277
Potential Threats to Bone Health in Pediatric IBD .....	278
Assessment of Bone Status in Children and Adolescents.....	280
Clinical Studies of Bone Health in Pediatric IBD.....	283
Potential Therapies for Bone Health in Pediatric IBD.....	285
Summary .....	287

**xvi Contents**

Chapter 22. Assessment of Growth and Nutritional Status in Pediatric Inflammatory Bowel Disease . . . . . 295  
*Babette Zemel*  
Introduction . . . . . 295  
Medical History and Laboratory Evaluation . . . . . 295  
Anthropometry . . . . . 296  
Skeletal Maturation . . . . . 302  
Sexual Maturation . . . . . 303  
Summary . . . . . 304

**Section 4 Medical Therapy**

Chapter 23. Pharmacogenetics in Inflammatory Bowel Disease . . . . . 309  
*Marla C. Dubinsky*  
Introduction . . . . . 309  
A Historical Perspective of TPMT Pharmacogenetics . . . . . 309  
Pharmacology of Thiopurines . . . . . 311  
The Clinical Application of TPMT Pharmacogenetics . . . . . 312  
Pharmacokinetics: The Role of Metabolite Monitoring . . . . . 313  
Conclusion . . . . . 314

Chapter 24. 5-Aminosalicylate Therapy . . . . . 317  
*M. Susan Moyer*  
Introduction . . . . . 317  
Pharmacokinetics . . . . . 317  
Mechanism of Action . . . . . 320  
Indications and Efficacy . . . . . 320  
Safety and Side Effects . . . . . 323  
Adherence . . . . . 324  
Future Directions . . . . . 324

Chapter 25. Antibiotic Therapy . . . . . 329  
*Douglas Jacobstein and Howard Kader*  
Introduction . . . . . 329  
Antibiotic Use in Crohn Disease . . . . . 330  
Antibiotics in Ulcerative Colitis . . . . . 332  
Emerging Therapies . . . . . 333  
Summary . . . . . 334

Chapter 26. Nutritional Therapy . . . . . 337  
*Wael El Matary and Mary Zachos*  
Introduction . . . . . 337  
Nutritional Impairment in Pediatric Inflammatory Bowel Disease . . . . . 337  
General Management of Nutrition in Inflammatory Bowel Disease . . . . . 339  
Adverse Effects of Enteral Nutrition . . . . . 345  
Mechanisms of Enteral Nutrition . . . . . 346  
Conclusions . . . . . 347

Chapter 27. Probiotic Therapy . . . . . 351  
*David R. Mack*  
Introduction . . . . . 351  
Ulcerative Colitis . . . . . 352  
Pouchitis . . . . . 354

	Crohn's Disease .....	355
	Associated Conditions .....	357
	Summary .....	357
Chapter 28.	Corticosteroid Therapy .....	363
	<i>Johanna C. Escher</i>	
	Introduction.....	363
	The Working Mechanism of Corticosteroids.....	363
	Systemic Corticosteroids .....	364
	Topical Corticosteroids.....	364
	Efficacy of Oral Budesonide Treatment in Crohn Disease .....	365
	Side Effects of Budesonide in Children.....	366
	Maintenance Treatment in Crohn Disease.....	368
	Budesonide Enemas in Ulcerative Colitis.....	368
	Conclusion .....	368
Chapter 29.	6-Mercaptopurine Therapy .....	371
	<i>Carmen Cuffari</i>	
	Introduction.....	371
	Clinical Indication .....	371
	Drug Monitoring.....	373
	6-MP Toxicity.....	376
	Conclusions.....	376
Chapter 30.	Methotrexate Therapy .....	379
	<i>Joel R. Rosh</i>	
	Introduction.....	379
	Mechanism of Action .....	380
	Dose and Administration.....	381
	Efficacy .....	382
	Toxicity and Monitoring .....	383
	Summary .....	384
Chapter 31.	Infliximab Therapy .....	387
	<i>S��verine Vermeire, Gert Van Assche and Paul Rutgeerts</i>	
	Introduction.....	387
	Efficacy of Infliximab in Adult Crohn Disease.....	388
	Efficacy of Infliximab in Paediatric Crohn Disease.....	389
	Infliximab for Paediatric Ulcerative Colitis.....	392
	Side Effects and Safety Profile of Infliximab.....	393
	Summary .....	397
Chapter 32.	Biologic Therapies .....	403
	<i>Jeanne Tung and William J. Sandborn</i>	
	Introduction.....	403
	Anti-tumor Necrosis Factor.....	403
	Anti-adhesion.....	410
	Anti-interleukin 12/23 .....	413
	Anti-interleukin-2 Receptor (Anti-CD25).....	414
	Miscellaneous Biotechnology Agents .....	414

Chapter 33. Treatment of Perianal Crohn Disease Fistulae . . . . . 429  
*Mark T. Osterman and Gary R. Lichtenstein*  
Introduction . . . . . 429  
Background . . . . . 429  
Medical Treatment . . . . . 431  
Summary . . . . . 439

Chapter 34. Treatment of Fulminant Colitis . . . . . 447  
*Harland Winter*  
Case . . . . . 447  
Discussion . . . . . 449

**Section 5 Surgical Therapy**

Chapter 35. Surgical Management of Crohn's Disease . . . . . 455  
*Daniel von Allmen*  
Introduction . . . . . 455  
History of Surgical Therapy . . . . . 455  
Operative Indications . . . . . 456  
Surgical Emergencies . . . . . 457  
Elective Surgery . . . . . 458  
Surgical Therapy . . . . . 459  
Strictureplasty . . . . . 461  
Laparoscopy . . . . . 462  
Colonic Disease . . . . . 462  
Perineal Disease . . . . . 463  
Rectal Strictures . . . . . 463  
Impact of Medical Therapy . . . . . 464  
Post-operative Recurrence . . . . . 464  
Adjuvant Procedures . . . . . 464

Chapter 36. Surgical Treatment of Ulcerative Colitis . . . . . 469  
*Peter Mattei and John L. Rombeau*  
Introduction . . . . . 469  
Indications for Surgery . . . . . 469  
Surgical Procedures . . . . . 471  
Preparation for Surgery . . . . . 475  
Outcomes of Surgery . . . . . 476  
Complications . . . . . 477  
Current Trends and Future Considerations . . . . . 479  
Summary . . . . . 480

Chapter 37. Pouchitis After Ileal Pouch-Anal Anastomosis . . . . . 485  
*Christine Carter-Kent and Robert Wyllie*  
Introduction . . . . . 485  
Definition and Incidence . . . . . 486  
Etiology and Pathogenesis . . . . . 486  
Diagnosis . . . . . 488  
Classification . . . . . 489  
Treatment . . . . . 490  
Outcome . . . . . 491  
Summary . . . . . 493



Chapter 38. Enteral Feeding Devices and Ostomies . . . . . 495  
*Susan N. Peck*  
 Gastrostomy . . . . . 495  
 Complications of Gastrostomy/Gastrojejunostomy Tubes . . . . . 496  
 Ostomy Education and Management . . . . . 501

**Section 6 Research**

Chapter 39. Clinical Indices for Pediatric Inflammatory Bowel Disease Research . . . . . 507  
*Angela Noble and Dan Turner*  
 Introduction . . . . . 507  
 Assessment of Instruments Used in Clinical Research . . . . . 507  
 Outcomes for Clinical Research in Paediatric Inflammatory Bowel Disease . . . . . 509  
 Gastrointestinal Endoscopy Indices . . . . . 515  
 Quality of Life Instruments . . . . . 516  
 Summary . . . . . 516  
 Appendix A . . . . . 521  
 Appendix B . . . . . 525  
 Appendix C . . . . . 526  
 Appendix D . . . . . 530

Chapter 40. Clinical Trials (Clinical Perspective) . . . . . 531  
*Salvatore Cucchiara and Osvaldo Borrelli*  
 Introduction . . . . . 531  
 Markers and Indexes of Disease Activity . . . . . 531  
 Quality of Life . . . . . 536  
 Summary . . . . . 537

Chapter 41. Clinical Trials (Industry Perspective) . . . . . 541  
*Allan David Olson*  
 Introduction . . . . . 541  
 Key Players in the Drug Development Process . . . . . 541  
 Drug Development Process . . . . . 543  
 Key Clinical Trial Design Features . . . . . 545  
 The Regulatory Agencies and the Regulatory Process . . . . . 545  
 Good Clinical Practice . . . . . 545  
 Practicing Physicians and Conduct of Clinical Trials . . . . . 547  
 Economics of Drug Development . . . . . 548  
 Unique Issues in Pediatric Research: Dosing and Consent/Assent . . . . . 549  
 Impact of the Pediatric Rule(s) . . . . . 549  
 Summary . . . . . 549  
 Glossary of acronyms . . . . . 550  
 Websites . . . . . 551

**Section 7 Special Considerations**

Chapter 42. Psychological Aspects of Pediatric Inflammatory Bowel Disease . . . . . 555  
*Laura M. Mackner and Wallace V. Crandall*  
 Introduction . . . . . 555  
 Behavioral/Emotional Functioning . . . . . 555  
 Social Functioning . . . . . 558  
 Family Functioning . . . . . 559

	Body Image and Self-esteem .....	559
	Stress and Coping .....	560
	Eating Problems.....	560
	Education .....	560
	Psychotherapy and Other Resources.....	561
	Summary .....	561
Chapter 43.	Measurement of Quality of Life in Pediatric Inflammatory Bowel Disease . . .	565
	<i>Anthony Otley</i>	
	Introduction.....	565
	Quality of Life: Concepts/Definitions.....	565
	Health-related Quality of Life Assessment in Pediatrics .....	568
	Health-related Quality of Life Assessment in Inflammatory Bowel Disease: Adult IBD Perspective .....	569
	Health-related Quality of Life Assessment in Pediatric Inflammatory Bowel Disease.....	571
	IMPACT .....	572
	Deficiencies in Current Knowledge and Areas for Future Research.....	576
Chapter 44.	Irritable Bowel Syndrome and Functional Gastrointestinal Disorders in Pediatric Inflammatory Bowel Disease . . . . .	581
	<i>Manu R. Sood</i>	
	Introduction.....	581
	Epidemiology.....	581
	Clinical Features .....	582
	Pathophysiology.....	583
	Diagnosis.....	586
	Treatment .....	587
	“Irritable” Pouch Syndrome .....	589
	Summary .....	589
Chapter 45.	Inflammatory Bowel Disease in Pregnancy . . . . .	593
	<i>Sunanda Kane</i>	
	Introduction.....	593
	Onset and Diagnosis During Pregnancy .....	593
	Contraception.....	593
	Fertility.....	594
	Effect of IBD on Pregnancy.....	595
	Effect of Pregnancy on IBD.....	595
	Management of IBD During Pregnancy .....	596
	Medical Therapies .....	596
	Immunomodulators .....	599
	Breastfeeding .....	602
	Mode of Delivery .....	603
	Surgery and Pregnancy.....	604
	Transition of Care.....	604
	Summary Points.....	605
Chapter 46.	Malignant Tumors Arising in Inflammatory Bowel Disease . . . . .	611
	<i>Thomas A. Ullman</i>	
	Introduction.....	611
	Pathogenesis and Molecular Basis of Cancer in IBD .....	611

	Colorectal Cancer in Ulcerative Colitis: Epidemiology and Clinical Practice ...	613
	Colorectal Cancer in Crohn Disease .....	622
	Crohn Disease and Adenocarcinoma of the Small Intestine .....	624
	Other Malignancies.....	624
	Summary .....	625
Chapter 47.	Quality Improvement in Inflammatory Bowel Disease . . . . .	631
	<i>Richard B. Colletti and Peter A. Margolis</i>	
	Introduction.....	631
	Variation in Care .....	632
	The Chronic Illness Care Model .....	633
	The Need for Quality Improvement in IBD .....	634
	The Improvement Model.....	635
	The Improvement Collaborative .....	636
	Collaborative Networks.....	638
Chapter 48A.	Advocacy for Pediatric Patients with Inflammatory Bowel Disease . . . . .	641
	<i>Janis Arnold, Athos Bousvaros, and Jennifer C. Jaff</i>	
	Introduction.....	641
	Advocacy Directed at Schools .....	641
	Advocacy Directed at Insurance Companies .....	644
	Social Security Disability .....	648
	Family and Medical Leave for Caregivers .....	649
	Summary .....	650
	Appendix 1. Sample Letter for Patient’s Student File Regarding Educational Accommodations Needed for an IBD Diagnosis .....	650
	Appendix 2. Preparing an Effective Insurance Company Letter of Medical Necessity .....	651
	Appendix 3. Sample Letter for Appeal of Denial of Mental Health Benefits .....	652
	Appendix 4. Social Security Listing of Impairments for Children with IBD ....	652
	Appendix 5. Preparing an Effective Letter for Family Medical Leave Act Provisions.....	653
Chapter 48B.	Legislative Advocacy . . . . .	655
	<i>Suzanne Rosenthal</i>	
	Introduction.....	655
	Legislative Initiatives .....	656
	Looking Back One Could Ask.....	658
Chapter 49.	Transition from Pediatric to Adult Care . . . . .	661
	<i>George D. Ferry and M. Susan Moyer</i>	
	Introduction.....	661
	Background.....	662
	Who is the Target.....	662
	Goals/objectives.....	662
	Transition Steps .....	663
	Monitoring the Process.....	664

# Contributors

**Janis Arnold, LICSW**

Pediatric Clinical Social Worker  
Inflammatory Bowel Disease Center  
Division of Gastroenterology and Nutrition  
Boston Children's Hospital  
Boston, Massachusetts

**Robert N. Baldassano, MD**

Professor  
University of Pennsylvania School of Medicine  
Attending Physician and Director, Inflammatory Bowel  
Disease Center  
The Children's Hospital of Philadelphia  
Philadelphia, Pennsylvania

**Cheryl Blank, DO**

Assistant Professor of Pediatrics  
University of Pittsburgh School of Medicine  
Department of Gastroenterology  
Children's Hospital of Pittsburgh of UPMC  
Pittsburgh, Pennsylvania

**Osvaldo Borrelli, MD**

Pediatric Gastroenterology and Liver Unit  
Pediatric Inflammatory Bowel Disease Center  
University of Rome "La Sapienza"  
Rome, Italy

**Athos Bousvaros, MD, MPH**

Associate Director, Inflammatory Bowel Disease Center  
Boston Children's Hospital  
Boston, Massachusetts

**Christine Carter-Kent, MD**

Pediatric Gastroenterology  
Cleveland Clinic Foundation  
Cleveland, Ohio